HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: clinchem.2005.054312v1 51/10/1883    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (7) Citing Articles via Google Scholar Google Scholar Articles by Tripodi, A. Articles by Mannucci, P. M. Search for Related Content PubMed PubMed Citation Articles by Tripodi, A. Articles by Mannucci, P. M. Related Collections Clinical Immunology Hemostasis and Thrombosis Hematology

Lupus Anticoagulants and Their Relationship with the Inhibitors against Coagulation Factor VIII: Considerations on the Differentiation between the 2 Circulating Anticoagulants

¹ Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine and Dermatology, University and Foundation IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy;² IRCCS Istituto Auxologico Italiano, Milan, Italy;

^aaddress correspondence to this author at: Via Pace 9, 20122 Milan, Italy; fax 39-02-50320723, e-mail armando.tripodi@unimi.it)

The first 300 words of the full text of this article appear below.

Lupus anticoagulants (LAs) are a heterogeneous group of immunoglobulins directed against negatively charged phospholipids in complex with proteins [ß₂-glycoprotein I (ß₂GPI), prothrombin and others] (1). LAs prolong phospholipid-dependent coagulation tests and are associated with increased risk of thrombosis and fetal loss (1). There are other types of anti-phospholipid (aPL) antibodies with or without LA activity that are detected by ELISAs that use as capture antigen cardiolipin, ß₂GPI, or prothrombin (1). Although the exact distribution of the 2 types of antibodies is unknown, it is widely accepted that LAs and aPL antibodies coexist in a large number of patients classified as having the antiphospholipid syndrome.

The relationship of these factors to inhibitors of individual coagulation factors seen in other conditions is controversial. Among the inhibitors of individual coagulation factors, those that inhibit factor VIII (anti-FVIII) are the most frequent, with an estimated incidence of 30% in patients with severe hemophilia A (2). They may also occur in nonhemophiliacs, producing a clinical condition known as acquired hemophilia (2). Anti-FVIII inhibitors bind to FVIII over a period of time and are associated with the risk of bleeding (3). Although LA and anti-FVIII inhibitors are dissimilar in terms of target and clinical presentation, they are somewhat related, as both of them prolong the phospholipid-dependent coagulation tests. Over the years there has been much debate on the possibility that some hemophiliacs may bear both types of anticoagulants (4)(5)(6), but this is still an unresolved question because tests to detect LA without interference from the anti-FVIII inhibitors are lacking (7).

In an attempt to clarify these issues and to explore the suitability of current diagnostic strategies to differentiate LAs from specific inhibitors to . . . [Full Text of this Article]

The following articles in journals at HighWire Press have cited this article:

				A Tripodi Testing for lupus anticoagulants: all that a clinician should know Lupus, April 1, 2009; 18(4): 291 - 298. [Abstract] [PDF]

				B. Giannakopoulos, F. Passam, Y. Ioannou, and S. A. Krilis How we diagnose the antiphospholipid syndrome Blood, January 29, 2009; 113(5): 985 - 994. [Abstract] [Full Text] [PDF]

				A. Tripodi Laboratory Testing for Lupus Anticoagulants: A Review of Issues Affecting Results Clin. Chem., September 1, 2007; 53(9): 1629 - 1635. [Abstract] [Full Text] [PDF]